ReviewAdvanced drug delivery reviews2012
Gene delivery to bone.
Review in Advanced drug delivery reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 133 citations in OpenAlex.
- Photoactivatable CRISPR/Cas13d via upconversion nanoparticles for deep tissue RNA engineering and orthopedic therapy.Nature communications · 2026Article
- A green-electrospun nanofibrous scaffold incorporating polyethylenimine-modified liposomes for sustained BMP2 gene delivery and enhanced osteogenic differentiation.Frontiers in bioengineering and biotechnology · 2026Article
- Engineering bone tissue with mRNA: from molecular design and delivery to clinical applications.Materials today (Kidlington, England) · 2025Article
- Therapeutic Potential of Nano-Sustained-Release Factors for Bone Scaffolds.Journal of functional biomaterials · 2025Review
- Repair mechanisms of bone system tissues based on comprehensive perspective of multi-omics.Cell biology and toxicology · 2025Review
- Research progress of gene therapy combined with tissue engineering to promote bone regeneration.APL bioengineering · 2024Review
- Direct Reprogramming of Fibroblasts to Osteoblasts: Techniques and Methodologies.Stem cells translational medicine · 2024Review
- Bioactive Materials for Bone Regeneration: Biomolecules and Delivery Systems.ACS biomaterials science & engineering · 2023Review
- Layered Double Hydroxides: A Novel Promising 2D Nanomaterial for Bone Diseases Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Osteoimmunology: The effect of autoimmunity on fracture healing and skeletal analysis.Forensic science international. Synergy · 2023Review
- Comparison ofBiofabrication · 2022Article
- What Has Immunology Brought to Periodontal Disease in Recent Years?Archivum immunologiae et therapiae experimentalis · 2022Review
- Lipid-Based Nano-Sized Cargos as a Promising Strategy in Bone Complications: A Review.Nanomaterials (Basel, Switzerland) · 2022Review
- Controlled Co-delivery of pPDGF-B and pBMP-2 from intraoperatively bioprinted bone constructs improves the repair of calvarial defects in rats.Biomaterials · 2022Article
- Engineered adipose-derived stem cells with IGF-1-modified mRNA ameliorates osteoarthritis development.Stem cell research & therapy · 2022Article
- Bone Augmentation for Implant Placement: Recent Advances.International journal of dentistry · 2022Review
- Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications.Gene therapy · 2021Article
- Gene therapy for bone healing: lessons learned and new approaches.Translational research : the journal of laboratory and clinical medicine · 2021Review
- Orthopaedic Gene Therapy: Twenty-Five Years On.JBJS reviews · 2021Article
- Gene- and RNAi-activated scaffolds for bone tissue engineering: Current progress and future directions.Advanced drug delivery reviews · 2021Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
Gene delivery to bone is useful both as an experimental tool and as a potential therapeutic strategy. Among its advantages over protein delivery are the potential for directed, sustained and regulated expression of authentically processed, nascent proteins. Although no clinical trials have been initiated, there is a substantial pre-clinical literature documenting the successful transfer of genes to bone, and their intraosseous expression. Recombinant vectors derived from adenovirus, retrovirus and lentivirus, as well as non-viral vectors, have been used for this purpose. Both ex vivo and in vivo strategies, including gene-activated matrices, have been explored. Ex vivo delivery has often employed mesenchymal stem cells (MSCs), partly because of their ability to differentiate into osteoblasts. MSCs also have the potential to home to bone after systemic administration, which could serve as a useful way to deliver transgenes in a disseminated fashion for the treatment of diseases affecting the whole skeleton, such as osteoporosis or osteogenesis imperfecta. Local delivery of osteogenic transgenes, particularly those encoding bone morphogenetic proteins, has shown great promise in a number of applications where it is necessary to regenerate bone. These include healing large segmental defects in long bones and the cranium, as well as spinal fusion and treating avascular necrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.